Review




Structured Review

Proteintech sr b1
S-nitrosylation of HINT1 aggravates ox-LDL induced foam cell formation through upregulating scavenger receptor A1 and CD36. (A) Representative images and quantification of oil red O staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 50 μm. (B) Representative images and quantification of lipid droplet staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 5 μm. (C) Total cholesterol level in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (D) Representative images and quantification of Dil-ox-LDL uptake in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without Dil-ox-LDL (40 μg/mL) ( n = 6). Scale bar: 20 μm. (E) Cholesterol efflux to HDL was evaluated in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A and treated with or without ox-LDL (100 μg/mL) ( n = 6). (F) Western blot analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (G) Western blot analysis of <t>SR-B1,</t> ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (H) qPCR analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (I) qPCR analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Data are presented as mean ± SEM. One-way ANOVA was used in A–C and E–I. Unpaired t -test was used in D.
Sr B1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+sr+bi/SR-BI+Antibody/pmc12886079-52-4-39
Average 94 stars, based on 33 article reviews
sr b1 - by Bioz Stars, 2026-09
94/100 stars

Images

1) Product Images from "S-nitrosylation of HINT1 in macrophages aggravates foam cell formation and atherosclerosis"

Article Title: S-nitrosylation of HINT1 in macrophages aggravates foam cell formation and atherosclerosis

Journal: Redox Biology

doi: 10.1016/j.redox.2026.104063

S-nitrosylation of HINT1 aggravates ox-LDL induced foam cell formation through upregulating scavenger receptor A1 and CD36. (A) Representative images and quantification of oil red O staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 50 μm. (B) Representative images and quantification of lipid droplet staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 5 μm. (C) Total cholesterol level in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (D) Representative images and quantification of Dil-ox-LDL uptake in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without Dil-ox-LDL (40 μg/mL) ( n = 6). Scale bar: 20 μm. (E) Cholesterol efflux to HDL was evaluated in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A and treated with or without ox-LDL (100 μg/mL) ( n = 6). (F) Western blot analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (G) Western blot analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (H) qPCR analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (I) qPCR analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Data are presented as mean ± SEM. One-way ANOVA was used in A–C and E–I. Unpaired t -test was used in D.
Figure Legend Snippet: S-nitrosylation of HINT1 aggravates ox-LDL induced foam cell formation through upregulating scavenger receptor A1 and CD36. (A) Representative images and quantification of oil red O staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 50 μm. (B) Representative images and quantification of lipid droplet staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 5 μm. (C) Total cholesterol level in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (D) Representative images and quantification of Dil-ox-LDL uptake in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without Dil-ox-LDL (40 μg/mL) ( n = 6). Scale bar: 20 μm. (E) Cholesterol efflux to HDL was evaluated in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A and treated with or without ox-LDL (100 μg/mL) ( n = 6). (F) Western blot analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (G) Western blot analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (H) qPCR analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (I) qPCR analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Data are presented as mean ± SEM. One-way ANOVA was used in A–C and E–I. Unpaired t -test was used in D.

Techniques Used: Staining, Transfection, Western Blot

Related Articles

SDS Page:

Article Title: Syncytin-1 deficiency impairs placental nutrient transport via PI3K/Akt/mTOR signaling.
Article Snippet: The placenta, a vital organ bridging the fetus and mother, governs nutrient exchange.. Syncytin-1, an endogenous retroviral envelope protein specifically expressed in placental trophoblasts, is diminished in preeclampsia and fetal growth restriction.. This study aimed to investigate the effects of low syncytin1 expression on placental transport of amino acids, fatty acids and cholesterol, and its implications for fetal and placental development, contributing to fetal growth restriction pathogenesis.

Membrane:

Article Title: Syncytin-1 deficiency impairs placental nutrient transport via PI3K/Akt/mTOR signaling.
Article Snippet: The placenta, a vital organ bridging the fetus and mother, governs nutrient exchange.. Syncytin-1, an endogenous retroviral envelope protein specifically expressed in placental trophoblasts, is diminished in preeclampsia and fetal growth restriction.. This study aimed to investigate the effects of low syncytin1 expression on placental transport of amino acids, fatty acids and cholesterol, and its implications for fetal and placental development, contributing to fetal growth restriction pathogenesis.

Incubation:

Article Title: Syncytin-1 deficiency impairs placental nutrient transport via PI3K/Akt/mTOR signaling.
Article Snippet: The placenta, a vital organ bridging the fetus and mother, governs nutrient exchange.. Syncytin-1, an endogenous retroviral envelope protein specifically expressed in placental trophoblasts, is diminished in preeclampsia and fetal growth restriction.. This study aimed to investigate the effects of low syncytin1 expression on placental transport of amino acids, fatty acids and cholesterol, and its implications for fetal and placental development, contributing to fetal growth restriction pathogenesis.

other:

Article Title: Photobiomodulation therapy promotes the ATP‐binding cassette transporter A1‐dependent cholesterol efflux in macrophage to ameliorate atherosclerosis
Article Snippet: The following antibodies were used: anti‐ABCA1 (ab18180, abcam); anti‐ABCG1 (ab52617, abcam); anti‐β‐actin (sc‐47778, santa cruz); anti‐SP1 (NB600‐232, Novus Biologicals); anti‐PKCζ (26899‐1‐AP, proteintech; sc‐17781, santa cruz); anti‐pPKCζ (9378, CST); anti‐α‐SMA (14395‐1‐AP, proteintech); anti‐CD11b (ab184308, abcam); anti‐GADPH (sc‐47724, santa cruz); anti‐SR‐BI (21277‐1‐AP, proteintech); anti‐CD36 (18836‐1‐AP, proteintech) and anti‐SR‐AI (sc‐166184, santa cruz).

Article Title: Identification of claudin-3 as an entry factor for rat hepacivirus
Article Snippet: Anti-CLDN1 (Invitrogen, RF217968), anti-CLDN3 (Abcam, ab15102), anti-SR-BI (Proteintech, 21277-1-AP), anti-OCLN (Abcam, ab216327), anti-β-actin (Sigma‒Aldrich, A5441), PE-conjugated anti-mouse/rat CD81 (BD Pharmingen, 559519), and PE-conjugated hamster IgG (BD Pharmingen, 553972) were purchased.



Similar Products

93
Novus Biologicals sr bi
Sr Bi, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+sr+bi/SR-BI+Antibody+-+BSA+Free/pm42031929-123-39-41
Average 93 stars, based on 1 article reviews
sr bi - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

93
Novus Biologicals sr bi antibody
Sr Bi Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+sr+bi/SR-BI+Antibody/pm41967385-165-32-34
Average 93 stars, based on 1 article reviews
sr bi antibody - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

94
Proteintech sr b1
S-nitrosylation of HINT1 aggravates ox-LDL induced foam cell formation through upregulating scavenger receptor A1 and CD36. (A) Representative images and quantification of oil red O staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 50 μm. (B) Representative images and quantification of lipid droplet staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 5 μm. (C) Total cholesterol level in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (D) Representative images and quantification of Dil-ox-LDL uptake in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without Dil-ox-LDL (40 μg/mL) ( n = 6). Scale bar: 20 μm. (E) Cholesterol efflux to HDL was evaluated in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A and treated with or without ox-LDL (100 μg/mL) ( n = 6). (F) Western blot analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (G) Western blot analysis of <t>SR-B1,</t> ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (H) qPCR analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (I) qPCR analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Data are presented as mean ± SEM. One-way ANOVA was used in A–C and E–I. Unpaired t -test was used in D.
Sr B1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+sr+bi/SR-BI+Antibody/pmc12886079-52-4-39
Average 94 stars, based on 1 article reviews
sr b1 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
Proteintech anti abca1 antibody
S-nitrosylation of HINT1 aggravates ox-LDL induced foam cell formation through upregulating scavenger receptor A1 and CD36. (A) Representative images and quantification of oil red O staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 50 μm. (B) Representative images and quantification of lipid droplet staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 5 μm. (C) Total cholesterol level in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (D) Representative images and quantification of Dil-ox-LDL uptake in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without Dil-ox-LDL (40 μg/mL) ( n = 6). Scale bar: 20 μm. (E) Cholesterol efflux to HDL was evaluated in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A and treated with or without ox-LDL (100 μg/mL) ( n = 6). (F) Western blot analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (G) Western blot analysis of <t>SR-B1,</t> ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (H) qPCR analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (I) qPCR analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Data are presented as mean ± SEM. One-way ANOVA was used in A–C and E–I. Unpaired t -test was used in D.
Anti Abca1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+sr+bi/SR-BI+Antibody/pmc13050004-109-35-37
Average 94 stars, based on 1 article reviews
anti abca1 antibody - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
Proteintech anti sr b1 antibody
S-nitrosylation of HINT1 aggravates ox-LDL induced foam cell formation through upregulating scavenger receptor A1 and CD36. (A) Representative images and quantification of oil red O staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 50 μm. (B) Representative images and quantification of lipid droplet staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 5 μm. (C) Total cholesterol level in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (D) Representative images and quantification of Dil-ox-LDL uptake in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without Dil-ox-LDL (40 μg/mL) ( n = 6). Scale bar: 20 μm. (E) Cholesterol efflux to HDL was evaluated in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A and treated with or without ox-LDL (100 μg/mL) ( n = 6). (F) Western blot analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (G) Western blot analysis of <t>SR-B1,</t> ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (H) qPCR analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (I) qPCR analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Data are presented as mean ± SEM. One-way ANOVA was used in A–C and E–I. Unpaired t -test was used in D.
Anti Sr B1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+sr+bi/SR-BI+Antibody/pmc13050004-109-30-32
Average 94 stars, based on 1 article reviews
anti sr b1 antibody - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
Proteintech anti scarb1
S-nitrosylation of HINT1 aggravates ox-LDL induced foam cell formation through upregulating scavenger receptor A1 and CD36. (A) Representative images and quantification of oil red O staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 50 μm. (B) Representative images and quantification of lipid droplet staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 5 μm. (C) Total cholesterol level in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (D) Representative images and quantification of Dil-ox-LDL uptake in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without Dil-ox-LDL (40 μg/mL) ( n = 6). Scale bar: 20 μm. (E) Cholesterol efflux to HDL was evaluated in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A and treated with or without ox-LDL (100 μg/mL) ( n = 6). (F) Western blot analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (G) Western blot analysis of <t>SR-B1,</t> ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (H) qPCR analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (I) qPCR analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Data are presented as mean ± SEM. One-way ANOVA was used in A–C and E–I. Unpaired t -test was used in D.
Anti Scarb1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+sr+bi/SR-BI+Antibody/pm41485681-107-24-25
Average 94 stars, based on 1 article reviews
anti scarb1 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


S-nitrosylation of HINT1 aggravates ox-LDL induced foam cell formation through upregulating scavenger receptor A1 and CD36. (A) Representative images and quantification of oil red O staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 50 μm. (B) Representative images and quantification of lipid droplet staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 5 μm. (C) Total cholesterol level in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (D) Representative images and quantification of Dil-ox-LDL uptake in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without Dil-ox-LDL (40 μg/mL) ( n = 6). Scale bar: 20 μm. (E) Cholesterol efflux to HDL was evaluated in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A and treated with or without ox-LDL (100 μg/mL) ( n = 6). (F) Western blot analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (G) Western blot analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (H) qPCR analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (I) qPCR analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Data are presented as mean ± SEM. One-way ANOVA was used in A–C and E–I. Unpaired t -test was used in D.

Journal: Redox Biology

Article Title: S-nitrosylation of HINT1 in macrophages aggravates foam cell formation and atherosclerosis

doi: 10.1016/j.redox.2026.104063

Figure Lengend Snippet: S-nitrosylation of HINT1 aggravates ox-LDL induced foam cell formation through upregulating scavenger receptor A1 and CD36. (A) Representative images and quantification of oil red O staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 50 μm. (B) Representative images and quantification of lipid droplet staining in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Scale bar: 5 μm. (C) Total cholesterol level in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (D) Representative images and quantification of Dil-ox-LDL uptake in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without Dil-ox-LDL (40 μg/mL) ( n = 6). Scale bar: 20 μm. (E) Cholesterol efflux to HDL was evaluated in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A and treated with or without ox-LDL (100 μg/mL) ( n = 6). (F) Western blot analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (G) Western blot analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (H) qPCR analysis of SR-A1, CD36 and LOX-1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). (I) qPCR analysis of SR-B1, ABCA1 and ABCG1 in HINT1 KO BMDMs transfected with Lenti-WT or Lenti-C84A followed by treatment with or without ox-LDL (100 μg/mL) ( n = 6). Data are presented as mean ± SEM. One-way ANOVA was used in A–C and E–I. Unpaired t -test was used in D.

Article Snippet: Antibodys against CD36 (18836-1-AP), SR-B1 (21277-1-AP), ABCA1 (26564-1-AP), ABCG1 (13578-1-AP), USF-2 (16614-1-AP), GAPDH (60004-1-lg), β-actin (66009-1-lg), and Tubulin (11224-1-AP) for western blotting, His-tag (66005-1-lg), Flag-tag (20543-1-AP), and HA-tag (51064-2-AP; 66006-2-lg) for western blotting and immunoprecipitation assay were obtained from Proteintech (Chicago, IL, USA); antibody against HINT1 (sc-271790), SR-A1 (sc-166184) for immunoprecipitation assay and immunofluorescence, CD36 (sc-7309) for immunofluorescence, USF2 (sc-293443) for immunoprecipitation assay were obtained from Santa Cruz Biotechnology (CA, USA).

Techniques: Staining, Transfection, Western Blot